Overview

* Bolt Biotherapeutics ( BOLT ) Q3 collaboration revenue rises to $2.2 mln, doubling from last year

* Company's net loss for Q3 narrows significantly compared to the same period last year

* Cash balance of $38.8 mln expected to fund operations into 2027

Outlook

* Company anticipates cash balance to fund operations into 2027

* Bolt seeks partner for further development of BDC-3042

Result Drivers

* R&D expenses were $6.5 million for the quarter ended September 30, 2025, compared to $13.8 million for the same quarter in 2024

* STEP-UP DOSING - Co modified BDC-4182 trial protocol for step-up dosing after strong immune response at initial dose levels

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $2.17

Collabor mln

ation

Revenue

Q3 Net -$7.14

Income mln

Q3 Basic -$3.72

EPS

Q3 -$7.70

Income mln

from

Operatio

ns

Q3 $9.87

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Bolt Biotherapeutics Inc ( BOLT ) is $13.50, about 64.4% above its November 11 closing price of $4.81

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)